Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 12OTHER 7OTHER_GOV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 8Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Pathologic Complete Response 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1HER2 Positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Breast Diseases 1Advanced Non-small-cell Lung Cancer 1Advanced Gastric Cancer 1

Interventions

Surgical Procedures, Operative 2Dexamethasone 2temoporfin 1pomalidomide 1pembrolizumab 1nimotuzumab 1liposomal doxorubicin 1ledipasvir 1ibrutinib 1golimumab 1Vinorelbine 1Tomography, X-Ray Computed 1Thalidomide 1Sofosbuvir 1Rituximab 1Ribavirin 1Radiotherapy 1Radiation 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitoxantrone 1Mastectomy 1Irinotecan 1Infliximab 1Immunotherapy, Adoptive 1Hematologic Tests 1Drug Therapy 1Docetaxel 1Diagnostic Imaging 1Dermoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Recurrence × Docetaxel × Clear all
NCT01380275 2014-09-25

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Sarcoma

Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡